Mankind Pharma Profit Soars, EMS Wins Delhi Jal Board Order

Mankind Pharma delivered a strong financial performance for the first quarter ended June 30, 2026, marking significant growth in its consolidated net profit. Concurrently, EMS secured a substantial Letter of Intent from the Delhi Jal Board, signaling key developments across different sectors.

Mankind Pharma’s Robust Q1FY27 Performance

The pharmaceutical giant saw its consolidated net profit surge by 29.60% to Rs 568.06 crore for Q1FY27, a considerable increase from Rs 438.32 crore in the same period last year. This growth highlights the company’s operational efficiency and market strength.

The company’s performance on a standalone basis also reflected this upward trend, with net profit rising by 34.49%.

• Consolidated Net Profit: Rs 568.06 crore (up 29.60%)
• Standalone Net Profit: Rs 558.49 crore (up 34.49%)
• Consolidated Total Income: Rs 4,075.59 crore (up 11.65%)
• Standalone Total Income: Rs 2,998.01 crore (up 13.78%)

These figures underscore Mankind Pharma’s consistent revenue generation and profit expansion, reinforcing its position within the competitive pharmaceutical landscape for the fiscal quarter.

EMS Bags Significant Delhi Jal Board Contract

Separately, EMS announced the receipt of a substantial Letter of Intent (LoI) from the Delhi Jal Board, Delhi Sarkar. This order represents a significant win for the company, known for its specialized solutions.

The contract is valued at approximately Rs 158.29 crore, inclusive of GST, indicating a major project scope for EMS.

• Client: Delhi Jal Board, Delhi Sarkar
• Project Scope: Providing, laying, and jointing internal and peripheral sewer lines in Tikri Kalan GOC.
• Location: Under the command of the proposed STP at Tikri Kalan.
• Execution Timeline: Within 15 months.

EMS, which specializes in sewerage solutions, water supply systems, and water and waste treatment plants, is poised to leverage its expertise in executing this critical infrastructure project for Delhi.

Both companies demonstrate strategic advancements, with Mankind Pharma showing strong financial growth and EMS securing a pivotal government infrastructure contract, reflecting dynamic market activity.